# Opioid Overutilization Prevention and Opioid Use Disorder Treatment Programs

## Quick Reference Guide

### Concurrent Drug Utilization Review (cDUR) and Point of Sale Programs
These programs use our pharmacy claims processing to screen prescriptions at point-of-sale for possible inappropriate drug prescribing, utilization and safety concerns.

| **Cumulative morphine milligram equivalents (MME) Dose** | - Cumulative point of sale dosage limit for all opioid products over MME 90  
- Requires intervention from dispensing pharmacist to determine if therapy is medically appropriate |
| --- | --- |
| **Drug-Drug Interaction – Opioids + Drugs to Treat Opioid Use Disorder (OUD)** | - Opioid claim will deny if a member has filled a drug to treat OUD within the past 30 days  
- Edit does not impede access to the treatment for OUD  
- Dispensing pharmacist can override the error if, in their professional judgment, the therapy is medically appropriate |
| **Maximum Acetaminophen Dosing** | - Combination opioids plus acetaminophen (APAP) limit  
- Point of sale quantity limit  
- Prevents doses of APAP greater than 4 grams per day |
| **Duplicative Therapy Edit – Long Acting Opioids** | - Point of sale edit if member is taking more than one long acting opioid  
- Requires intervention from dispensing pharmacist to determine if therapy is medically appropriate |
| **Drug-Drug Interaction – Opioids + Benzodiazepines** | - Point of sale edit if member is taking opioids and benzodiazepines concurrently  
- Requires intervention from dispensing pharmacist to determine if therapy is medically appropriate and to educate patient on risk of taking these medications together |

### Utilization Management Programs
These programs allow for the evaluation of a patient's drug therapy before medication is dispensed and help ensure safe, appropriate and cost-effective drug utilization.

| **Prior Authorization/Medical Necessity** | Prior Authorization to ensure appropriate use and medical necessity  
- Doses above formulary quantity limits on all opioid products  
- Transmucosal Fentanyl Products (High risk products)  
- Most long acting opioids  
- Pediatric Tramadol and Codeine |
| --- | --- |
| **Access to Medication-Assisted Treatment** | - No Prior Authorization for preferred products (i.e. generic buprenorphine/naloxone sublingual tablet, Suboxone® sublingual film)  
- Prior Authorization for higher cost products to ensure appropriate use |
| **Access to Overdose Prevention Medication (naloxone)** | - No prior authorization is required for preferred naloxone products (Generic naloxone injection and Narcan® Nasal Spray)  
- No quantity limit on generic; Quantity limit of 2 on brand Narcan® product |
| **7 Day First Prescription Fill Limit for Patients New to Therapy** | - 7 day dispensing limits for opioids for opioid naïve members |

Updated 12/1/2018
### Retrospective Drug Utilization Review (rDUR) Programs

These programs review drug therapies after the patient has received the medications to screen for appropriate use and over utilization.

<table>
<thead>
<tr>
<th>Program</th>
<th>Details</th>
</tr>
</thead>
</table>
| DUR Program via Medication Therapy Management (MTM) program | - Identify potential inappropriate opioid utilization or members at risk for adverse events due to opioids  
- Pharmacists work directly with providers and can help develop taper plans if needed |
| MME 90 Member and Provider Letters                      | - Targeted letters to members and their prescribers who are on chronic opiates with doses greater than MME-90  
- Letters to providers also include information of benzodiazepine fill history |
| Other Programs                                          |                                                                         |
| Fraud/Waste/Abuse Monitoring and Detection              | - Retrospective controlled substance claims analysis  
- Identifies outlier opioid prescribers and members for further investigation |
| Case and Disease Management for Chronic Pain            | - Run by the Care Management Program  
- Patients can self-enroll or be referred into the program |
| Pathway To Treat- Persistent, Non-Malignant Pain        | - Educational material sent to prescribers and available on plans website  
- Includes information on safe prescribing practices for opioids, non-opioid options, naloxone use and how to taper opioids |
| Substance Use Disorder Helpline                         | - 24/7 helpline (855-780-5955) for members or caregivers staffed by licensed behavioral health providers |

Updated 12/1/2018